![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Xoma Discontinues All Gevokizumab Development Activities
Xoma Discontinues All Gevokizumab Development Activities
March 17, 2016
Biopharmaceutical company Xoma has ceased all development activities related to the monoclonal antibody gevokizumab.
The therapy was in Phase 3 testing for the treatment of pyoderma gangrenosum, but data from the 25-patient study did not demonstrate efficacy to warrant continuation, the company said. Xoma had been jointly developing the candidate with Les Laboratories Servier for a number of indications, none of which has panned out.
Upcoming Events
-
21Oct